cannabis hope drug firm prescription cannabis drug made uk biotech firm gw pharmaceutical set approved canada drug used treat central nervous system alleviate symptom multiple sclerosis m week ago share gw pharma lost third value uk regulator said wanted evidence drug's benefit canadian authority said sativex drug considered approval approximately 50 000 people canada diagnosed m 85 000 people suffering condition uk many patient already smoke cannabis relieve symptom gw pharma's sativex mouth spray could legally available m sufferer canada within next month first time cannabis based drug approved anywhere world representing landmark gw pharma patient m final approval canada little formality analyst said company expects full approval sativex early 2005 delighted receive qualifying notice health canada look forward receiving regulatory approval sativex canada early part 2005 said gw pharma executive chairman dr geoffrey guy uk government granted gw pharma licence grow cannabis plant medical research purpose satifex consists cannabis extract containing tetrahydrocannabinol cannabidiol cocktail also proved effective treating patient arthritis thousand plant grown secret location somewhere english countryside despite hope regulatory approval last year series delay put back sativex's launch uk latest news sent share gw pharma 5p 113 5p